UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1166 Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1285-A1285

2023

Volltextzugriff (PDF)

LILRB receptor-mediated regulation of myeloid cell maturation and function

Cancer Immunology, Immunotherapy, 2017-08, Vol.66 (8), p.1079-1087

2017

Volltextzugriff (PDF)

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity

The Journal of clinical investigation, 2018-12, Vol.128 (12), p.5647-5662

2018

Volltextzugriff (PDF)

DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance

Immunity (Cambridge, Mass.), 2015-06, Vol.42 (6), p.1143-1158

2015

Volltextzugriff (PDF)

Human placental hematopoietic stem cell-derived natural killer cells (CYNK) recognize and eliminate influenza A virus-infected cells

Frontiers in immunology, 2022-10, Vol.13, p.900624-900624

2022

Volltextzugriff (PDF)

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008656

2024

Volltextzugriff (PDF)

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001975

2021

Volltextzugriff (PDF)

Complement Regulation of T-Cell Alloimmunity

Seminars in nephrology, 2013-11, Vol.33 (6), p.565-574

2013

Volltextzugriff (PDF)

NK cells are required for costimulatory blockade induced tolerance to vascularized allografts

Transplantation, 2012-09, Vol.94 (6), p.575-584

2012

Volltextzugriff (PDF)

LILRB receptor-mediated regulation of myeloid cell maturation and function

Cancer Immunology, Immunotherapy, 2017-08, Vol.66 (8), p.1079-1087

2017

Volltextzugriff (PDF)

Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells

The Journal of experimental medicine, 2013-02, Vol.210 (2), p.257-268

2013

Volltextzugriff (PDF)

Abstract 513: Simultaneous monitoring of immune cell subsets and minimal residual disease in bone marrow aspirate using full-spectrum flow cytometry

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.513-513

2021

Volltextzugriff (PDF)

Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation

The Journal of immunology (1950), 2009-01, Vol.182 (1), p.259-273

2009

Volltextzugriff (PDF)

Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Mediate Protection Against Influenza A Viral Infection

Blood, 2020-11, Vol.136 (Supplement 1), p.2-3

2020

Volltextzugriff (PDF)

Abstract 4482: Monitoring T cell reactivity to allogeneic placental cell products using multiple lymphocyte reaction and TCR sequencing approaches

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4482-4482

2020

Volltextzugriff (PDF)

Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells

The Journal of immunology (1950), 2013-06, Vol.190 (12), p.5921-5925

2013

Volltextzugriff (PDF)

A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS478-TPS478

2023

Volltextzugriff (PDF)

Complement regulation of T cell immunity

Immunologic research, 2012-12, Vol.54 (1-3), p.247-253

2012

Volltextzugriff (PDF)

A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2080-TPS2080

2022

Volltextzugriff (PDF)

Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner

Blood, 2023-11, Vol.142 (Supplement 1), p.5750-5750

2023

Volltextzugriff (PDF)

Human Placental CD34 +-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies

Blood, 2021-11, Vol.138 (Supplement 1), p.2773-2773

2021

Volltextzugriff (PDF)

Abstract 2218: High affinity and cleavage resistant CD16 enhances Trastuzumab mediated killing of gastric cancer targets by human placental CD34+-derived natural killer cells

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2218-2218

2020

Volltextzugriff (PDF)

Development of CD19 CAR Engineered Human Placental CD34 +-Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy

Blood, 2021-11, Vol.138 (Supplement 1), p.2779-2779

2021

Volltextzugriff (PDF)

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.4457-4457

2019

Volltextzugriff (PDF)

Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) for ADCC Mediated Cancer Immunotherapy

Blood, 2020-11, Vol.136 (Supplement 1), p.1-1

2020

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(41)
Dissertationen
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Animals
(12)
Immunology
(12)
Humans
(11)
Mice
(11)
Mice, Inbred Balb C
(6)
Mice, Knockout
(6)
Female
(5)
Flow Cytometry
(5)
T-Lymphocytes, Regulatory - Immunology
(5)
Immunotherapy
(4)
Mice, Inbred C57bl
(4)
Cancer
(3)
Cell Activation
(3)
Cells, Cultured
(3)
Gene Expression
(3)
Graft Rejection - Immunology
(3)
Graft Rejection - Prevention & Control
(3)
Immunoglobulins
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1166 Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells

LILRB receptor-mediated regulation of myeloid cell maturation and function

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity

DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance

Human placental hematopoietic stem cell-derived natural killer cells (CYNK) recognize and eliminate influenza A virus-infected cells

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

Complement Regulation of T-Cell Alloimmunity

NK cells are required for costimulatory blockade induced tolerance to vascularized allografts

LILRB receptor-mediated regulation of myeloid cell maturation and function

Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells

Abstract 513: Simultaneous monitoring of immune cell subsets and minimal residual disease in bone marrow aspirate using full-spectrum flow cytometry

Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation

Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Mediate Protection Against Influenza A Viral Infection

Abstract 4482: Monitoring T cell reactivity to allogeneic placental cell products using multiple lymphocyte reaction and TCR sequencing approaches

Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells

A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Complement regulation of T cell immunity

A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM)

Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner

Human Placental CD34 +-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies

Abstract 2218: High affinity and cleavage resistant CD16 enhances Trastuzumab mediated killing of gastric cancer targets by human placental CD34+-derived natural killer cells

Development of CD19 CAR Engineered Human Placental CD34 +-Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) for ADCC Mediated Cancer Immunotherapy

Suchergebnisse filtern